BIOMARCADORES PARA DIAGNÓSTICO DE DEMENCIA

Volver

Resultados 59 resultados LastUpdate Última actualización 20/08/2018 [16:08:00] pdf PDF




Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Página1 de 3 nextPage   Mostrar por página


METHODS AND PROBES FOR DETERMINING THE CONCENTRATION OF COPPER

NºPublicación: US2018231574A1 16/08/2018

Solicitante:
IGEA RES CORPORATION [US]

Resumen de: US2018231574A1

The present invention relates to new probes and methods for determining the concentration of copper. In particular the present invention refers to a method for determining the concentration of “free” copper in a serum or blood sample with a high degree of sensitivity and accuracy.



traducir


 

METHOD AND KIT FOR DIAGNOSING ALZHEIMER'S DISEASE USING G72 PROTEIN AND SLC7A11 MRNA AS BIOMARKERS

NºPublicación: EP3361257A1 15/08/2018

Solicitante:
KAOHSIUNG CHANG GUNG MEMORIAL HOSPITAL [TW]

Resumen de: EP3361257A1

A method for diagnosing Alzheimer's disease (AD) includes the steps of: determining a biomarker level in a blood sample from a human subject suspected of having AD, the biomarker level being selected from the group consisting of a G72 protein level, an SLC7A11 mRNA expression level, and a combination thereof; comparing the biomarker level with a predetermined standard therefor; wherein an increase in the biomarker level relative to the predetermined standard therefor is indicative of AD in the human subject. A kit for diagnosing AD includes a material for determining the biomarker level and instructions for using the kit.



traducir


 

DIAGNOSTIC KIT FOR DIAGNOSING DISORDERS OR DISEASES RELATED TO ABNORMAL PROTEIN AGGREGATION OR MISFOLDING OF PROTEIN USING DISSOLUTION OF PROTEIN AGGREGATES

NºPublicación: CN108387738A 10/08/2018

Solicitante:
\u97E9\u56FD\u79D1\u5B66\u6280\u672F\u7814\u7A76\u9662

Resumen de: WO2014175693A1

The present invention relates to a diagnostic kit for diagnosing disorders or diseases related to abnormal protein aggregation or misfolding of protein by using dissolution of protein aggregates in the body, capable of accurately diagnosing disorders or diseases such as Alzheimer's disease caused by aggregation of beta amyloid, as well as disorders and diseases related to abnormal protein aggregation or misfolding of protein by analyzing concentrations through the dissolution of aggregated protein in the blood of a person having other disorders or diseases due to protein aggregation.



traducir


 

METHOD FOR MONITORING POST-TRANSLATIONAL MODIFICATION OF PROTEINS

NºPublicación: WO2018143531A1 09/08/2018

Solicitante:
KOREA INST SCI & TECH [KR]

Resumen de: WO2018143531A1

A disclosed method for monitoring post-translational modification of proteins comprises the following steps: preparing a first micro bead by binding a protein antibody to the surface of a base bead; preparing a second micro bead by binding a protein of interest having a first post-translational modification or a second post-translational modification, which are inversely proportional to each other, to the protein antibody of the first micro bead; preparing a third micro bead by binding the second micro bead to a first post-translationally modified antibody that selectively binds to the first post-translational modification of the protein of interest; preparing a fourth micro bead by binding the second micro bead to a second post-translationally modified antibody that selectively binds to the second post-translational modification of the protein of interest; measuring impedances of the third micro bead and the fourth micro bead, respectively; and obtaining a ratio of a first difference between the impedance of the third micro bead and a reference impedance to a second difference between the impedance of the fourth micro bead and the reference impedance.



traducir


 

METHODS AND COMPOUNDS FOR DETECTION AND BINDING OF ALEDHYDES

NºPublicación: WO2018141069A1 09/08/2018

Solicitante:
UNIV OTTAWA [CA]

Resumen de: WO2018141069A1

Methods of detecting an aldehyde-containing compound in a subject or in a sample from a subject are described herein, comprising administering an aldehyde-binding compound of Formula I to the subject, or combining such a compound with the sample; and detecting the product of the compound of Formula I and the aldehyde-containing compound. Detection of the product may involve imaging, such as MRI, CEST-MRI or positron emission tomography (PET) imaging; or may involve fluorescence or an electrochemical detection method. Biologically relevant aldehydes detected according to the described method can be used to monitor conditions such as brain injury, neurodegenerative disorders such as Alzheimer's disease, diabetes, heart disease, and cancer. Formula (I)



traducir


 

METHODS FOR DIAGNOSING AND TREATING ALZHEIMERS DISEASE USING G72 PROTEIN AND SLC7A11 mRNA AS BIOMARKERS

NºPublicación: US2018224468A1 09/08/2018

Solicitante:
KAOHSIUNG CHANG GUNG MEMORIAL HOSPITAL [TW]

Resumen de: US2018224468A1

A method for diagnosing Alzheimer's disease (AD) includes: obtaining a blood sample from a human subject suspected of having AD; determining a G72 protein level in the blood sample; determining an SLC7A11 mRNA expression level in the blood sample; comparing the G72 protein level with a first predetermined standard; comparing the SLC7A11 mRNA expression level with a second predetermined standard; and diagnosing the human subject with AD when the G72 protein level is higher than the first predetermined standard and the SLC7A11 mRNA expression level is higher than the second predetermined standard. An effective amount of a pharmaceutical composition may be administered to the diagnosed human subject for treating AD.



traducir


 

AMYLOID BETA DETECTION BY MASS SPECTROMETRY

NºPublicación: EP3356831A1 08/08/2018

Solicitante:
QUEST DIAGNOSTICS INVEST LLC [US]

Resumen de: US2017089917A1

Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (Aβ42) to amyloid beta 40 (Aβ40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.



traducir


 

IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF

NºPublicación: RU2017103527A 07/08/2018

Solicitante:
\u042D\u0411\u0411\u0412\u0418 \u0414\u041E\u0419\u0427\u041B\u0410\u041D\u0414 \u0413\u041C\u0411\u0425 \u0423\u041D\u0414 \u041A\u041E. \u041A\u0413

Resumen de: WO2016005328A2

The invention relates to immunogenic products based on muteinamyloid β(Aβ) amino acid sequences, in particular to oligomers of Aβ muteins, and to the use of said products in diagnosis, treatment and prevention of conditions such as amyloidoses, and for identifying agents capable of binding to said products.



traducir


 

アルツハイマー病におけるタウ媒介性病理のタンパク質ベースの治療および診断

NºPublicación: JP2018117631A 02/08/2018

Solicitante:
\u30A2\u30AF\u30BD\u30F3 \u30CB\u30E5\u30FC\u30ED\u30B5\u30A4\u30A8\u30F3\u30B9 \u30A8\u30B9\u30A8\u30FC

Resumen de: JP2018117631A

【課題】病理学的タウ−タウ相互作用の開始および伝播に寄与するタウタンパク質の領域に結合する独特の治療抗体および診断抗体、ならびにそれらのフラグメント、部分、誘導体およびバリアント、ならびにそれらを作製する方法を提供すること。【解決手段】本発明は、アルツハイマー病および関連タウオパチーの診断、予防および処置のためにそれらの抗体を使用する方法にも関する。本発明は、アルツハイマー病および他の神経変性タウオパチーの予防的および治療的な処置のための方法も提供する。この方法は、患者の脳における病理学的タウタンパク質およびタウ沈着物に対する免疫応答を誘発する抗体および/またはペプチドワクチンの注射を含む。好適なワクチンは、本明細書中に提供されるタウ治療用エピトープの1つもしくは複数を有するタウペプチドを表わす。【選択図】なし



traducir


 

METHOD FOR MONITORING POST-TRANSLATIONAL MODIFICATION OF PROTEIN

NºPublicación: US2018217164A1 02/08/2018

Solicitante:
KOREA INST SCI & TECH [KR]

Resumen de: US2018217164A1

According to a method for monitoring post-translational modifications of protein is provided, a first microbead by binding a protein antibody to a base bead is provided. A second microbead by binding a target protein having a first post-translational modification or a second post-translational modification, which are inversely proportional to each other, to the protein antibody of the first microbead, is provided. A third microbead by binding the second microbead to a first post-translational modification antibody is provided. A fourth microbead by binding the second microbead to a second post-translational modification antibody is provided. Impedances of the third and fourth microbeads are measured. A ratio of a first difference, between the impedances of the third microbead and a reference impedance, to a second difference, between the impedances of the fourth microbead and the reference impedance, is obtained.



traducir


 

METHOD FOR DETERMINING THE RISK OF DEVELOPING ALZHEIMER'S DISEASE

NºPublicación: JP2018521321A 02/08/2018

Solicitante:
\u30B3\u30F3\u30BB\u30DB\u30FB\u30B9\u30DA\u30EA\u30AA\u30FC\u30EB\u30FB\u30C7\u30FB\u30A4\u30F3\u30D9\u30B9\u30C6\u30A3\u30AC\u30B7\u30AA\u30CD\u30B9\u30FB\u30B7\u30A8\u30F3\u30C6\u30A3\u30D5\u30A3\u30AB\u30B9,
\u30C6\u30C8\u30E9\u30CB\u30E5\u30FC\u30ED\u30F3\u3001\u30BD\u30B7\u30A8\u30C0\u30C3\u30C9\u3001\u30EA\u30DF\u30BF\u30FC\u30C0\uFF34\uFF25\uFF34\uFF32\uFF21\uFF2E\uFF25\uFF35\uFF32\uFF2F\uFF2E \uFF33\uFF0E\uFF2C\uFF0E

Resumen de: WO2017001716A1

The present invention relates to an in vitro method for determining the risk of developing Alzheimer's disease or a cognitive disorder similar to said disease, to an in vitro method for designing a personalised therapy in a subject suffering from mild cognitive impairment, and to an in vitro method for selecting a patient who can be treated with a therapy for preventing and/or treating Alzheimer's or a cognitive disorder similar to said disease, the methods being based on determining the level of phosphorylation in threonine residues in E2F4 protein or in a functionally equivalent variant, in a sample from the subject. The invention also relates to the use of E2F4 or a functionally equivalent variant of same, wherein E2F4 or the variant is phosphorylated in threonine as a marker of the risk of developing Alzheimer's disease or a cognitive disorder similar to Alzheimer's disease. Lastly, the invention relates to a kit comprising a reagent capable of determining the level of E2F4 protein phosphorylation in threonine residues, and to the use of said kit.



traducir


 

Protein Damage in Aging and Age-Related Diseases

NºPublicación: US2018217133A1 02/08/2018

Solicitante:
MEDITERRANEAN INST FOR LIFE SCIENCES [HR]

Resumen de: US2018217133A1

The process of aging and the development of age-related diseases are related to the emerging phenotypes of increasingly damaged and progressively malfunctioning proteomes. The present invention provides methods of preventing aging and age-related diseases in mammals by assessment of protein-specific oxidative damage. Methods of providing treatments that reduce intracellular reactive oxygen and/or nitrogen species, or protein-specific damage caused by reactive oxygen and/or nitrogen species, are disclosed. Furthermore, methods of screening for compounds that reduce intracellular reactive oxidative species, and/or molecules that prevent protein-specific damage by protecting the susceptible protein from such damage and therefore prevent or treat degenerative or age-related diseases, are also disclosed.



traducir


 

METHOD FOR DIAGNOSIS OF ALZHEIMER'S DISEASE USING MICRORNA

NºPublicación: WO2018139759A1 02/08/2018

Solicitante:
BIORCHESTRA LTD [KR]

Resumen de: WO2018139759A1

The present invention relates to methods for the diagnosis of and providing information for the diagnosis of Alzheimer's disease or a brain disease using miR-485-3p and to a composition and a kit for the diagnosis of Alzheimer's disease or a brain disease. The present invention enables an objective data analysis of the diagnosis of Alzheimer's disease or a brain disease by measuring the expression level of miR-485-3p in blood, minimizes risks to a patient by measuring the concentration of amyloid beta 42 in saliva, and enables a quick and accurate diagnosis. Accordingly, the present invention is very useful for the prevention of Alzheimer's disease or a brain disease.



traducir


 

BIOMARKERS AND DIAGNOSTIC METHODS FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS

NºPublicación: US2018217165A1 02/08/2018

Solicitante:
NANOSOMIX INC [US]

Resumen de: US2018217165A1

The present invention relates to biomarkers and diagnostic and prognostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.



traducir


 

AGENTS INHIBITING KALLIKREIN-8 FOR USE IN THE PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE

NºPublicación: EP3353214A1 01/08/2018

Solicitante:
UNIV DUISBURG ESSEN [DE]

Resumen de: WO2017050803A1

The present invention relates to an agent which inhibits Kallikrein-8 for use in the treatment or prevention of Alzheimer's disease and / or its precursor stages, as well as to methods, kits and uses relating thereto, including diagnostic tools.



traducir


 

BORONDIFLUORIDE COMPLEXES OF CURCUMINOID COMPOUNDS, METHOD OF PREPARATION AND USES THEREOF

NºPublicación: KR20180086435A 31/07/2018

Solicitante:
UNIV DAIX MARSEILLE [FR]
CENTRE NATIONAL DE LA RECHERCHE SCIENT C N R S [FR]

Resumen de: EP3173416A1

The present invention relates to new borondifluoride complexes of curcuminoid compounds with an enhanced fluorescence quantum yield and emission, and their uses as fluorophore in various fields such as bioimaging, therapeutics, theranostics, display and telecommunication technologies, photovoltaics. The preparation said compounds is also described.



traducir


 

DIAGNOSTIC TEST FOR ALZHEIMER'S DISEASE BASED ON IDENTIFICATION OF A PROTEOLYTIC PATHWAY

NºPublicación: CN108348776A 31/07/2018

Solicitante:
\u5065\u5EB7\u7814\u7A76\u516C\u53F8

Resumen de: WO2017004385A1

A method for detecting circulating levels of beta amyloid peptides in an individual by administration of one or more inhibitors of an extracellular proteolytic pathway in blood and detection of the beta amyloid peptides in the blood or a fraction thereof. An example of an inhibitor is an anticoagulant. Levels of desired beta amyloid peptides such as Αβ1-40 and Αβ1-42 can be determined in the blood samples collected from the individuals.



traducir


 

TAU-BINDING ANTIBODIES

NºPublicación: JP2018519833A 26/07/2018

Solicitante:
\u30E6\u30FC\u30B7\u30FC\u30D3\u30FC \u30D0\u30A4\u30AA\u30D5\u30A1\u30EB\u30DE \u30A8\u30B9\u30D4\u30FC\u30A2\u30FC\u30EB\u30A8\u30EB

Resumen de: WO2017005732A1

The present invention relates to Tau-binding antibodies and binding fragments thereof.



traducir


 

Method for Treatment of Traumatic Brain Injury Targeting Aggregated Peptides

NºPublicación: US2018209994A1 26/07/2018

Solicitante:
BIOARCTIC NEUROSCIENCE AB [SE]

Resumen de: US2018209994A1

A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain. An agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain is suitable for use in preventing, alleviating or treating traumatic brain injury. A method for predication of the risk of an individual for complications after a traumatic brain injury comprises detecting one or more aggregated forms of one or more peptides prone to aggregate as a result of a traumatic brain injury event, in the brain of the individual, wherein an increased level of such aggregates in the brain indicates an increased risk for complications.



traducir


 

Method of identifying novel protein aggregation inhibitors based on chemical kinetics

NºPublicación: AU2016384317A1 26/07/2018

Solicitante:
CAMBRIDGE ENTERPRISE LTD

Resumen de: AU2016384317A1

The present invention relates to methods of identifying pharmacophores and inhibitors against protein aggregation. The present invention also provides pharmacophores themselves and medical uses of agents in the treatment of Alzheimer's.



traducir


 

ANTI-TAU ANTIBODIES AND METHODS OF USE

NºPublicación: JP2018519810A 26/07/2018

Solicitante:
\u30B8\u30A7\u30CD\u30F3\u30C6\u30C3\u30AF\uFF0C \u30A4\u30F3\u30B3\u30FC\u30DD\u30EC\u30A4\u30C6\u30C3\u30C9,
\u30A8\u30FC\u30B7\u30FC \u30A4\u30DF\u30E5\u30FC\u30F3 \u30A8\u30B9\uFF0E\u30A8\u30FC\uFF0E

Resumen de: WO2016196726A1

The invention provides anti-Tau antibodies and methods of using the same.



traducir


 

LACTOFERRIN FOR USE IN THE DIAGNOSIS OR PROGNOSIS OF ALZHEIMER'S DISEASE

NºPublicación: KR20180083909A 23/07/2018

Solicitante:
GEROA DIAGNOSTICS S L [ES]

Resumen de: EP3171174A1

The present invention is the protein of lactoferrin, or an encoding nucleic acid of same, for use in the diagnosis or prognosis of Alzheimer's disease (AD). The invention is a method of diagnosis or prognosis of AD in a subject, comprising assessing the level of lactoferrin in the saliva or in a saliva sample of said subject and determining whether said level is above or below a value of 6.5 µg/ml, wherein a value below 6.5 µg/ml is indicative of AD or of the prognosis of AD. Another aspect is a kit comprising at least one reagent, preferably an antibody, for the quantification of lactoferrin in the saliva or in a saliva sample of a subject enabling the comparison of said quantification with a predetermined cut-off value.



traducir


 

MODULAR CHEMIRESISTIVE SENSOR

NºPublicación: US2018202964A1 19/07/2018

Solicitante:
INNOSENSE LLC [US]

Resumen de: US2018202964A1

The present invention relates to methods of forming modular chemiresistive sensors. The sensors preferably have two gold or platinum electrodes mounted on a silicon substrate with the electrodes connected to a power source and are separated by a gap of 0.5 to 4.0 μm. Functionalized polymer nanowire or carbon nanotube span the gap between the electrodes and connect the electrodes electrically. The electrodes are further connected to a circuit board having a processor and data storage, where the processor measures current and voltage values between the electrodes and compares the current and voltage values with current and voltages values stored in the data storage and assigned to particular concentrations of a pre-determined substances.



traducir


 

METHOD FOR DIAGNOSING EARLY ONSET OF ALZHEIMER'S DISEASE OR MILD COGNITIVE IMPAIRMENT

NºPublicación: US2018202997A1 19/07/2018

Solicitante:
ANT LABS INC [KR]

Resumen de: US2018202997A1

Provided is a method for diagnosis of Alzheimer's disease or mild cognitive impairment. The method for diagnosis of Alzheimer's disease or mild cognitive impairment of the present invention identifies expression level of miR-206 of olfactory tissue, by which shows high diagnostic rate in diagnosis of Alzheimer's disease and mild cognitive impairment, allowing diagnosis at low cost and biopsy in high stability to lead a marked effect on diagnosis of Alzheimer's disease or mild cognitive impairment.



traducir


 

BIOMOLECULES INVOLVED IN ALZHEIMER'S DISEASE

Nº publicación: JP2018519505A 19/07/2018

Solicitante:
\u30A8\u30EC\u30AF\u30C8\u30ED\u30D5\u30A9\u30EC\u30C6\u30A3\u30AF\u30B9 \u30EA\u30DF\u30C6\u30C3\u30C9

Resumen de: WO2016189163A1

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2',3'-cyclic-nucleotide 3'-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver